mineralys therapeutics inc - MLYS
MLYS
Close Chg Chg %
26.41 0.56 2.12%
Closed Market
26.97
+0.56 (2.12%)
Volume: 1.65M
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: mineralys therapeutics inc - MLYS
MLYS Key Data
| Open $25.49 | Day Range 25.49 - 27.03 |
| 52 Week Range 10.44 - 47.65 | Market Cap $2.22B |
| Shares Outstanding 82.40M | Public Float 61.41M |
| Beta 0.69 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.38 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.45M |
MLYS Performance
| 1 Week | 13.89% | ||
| 1 Month | 1.43% | ||
| 3 Months | -24.47% | ||
| 1 Year | 117.50% | ||
| 5 Years | N/A |
MLYS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About mineralys therapeutics inc - MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
MLYS At a Glance
Mineralys Therapeutics, Inc.
150 North Radnor Chester Road
Radnor, Pennsylvania 19087
| Phone | 1-888-378-6240 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -154,651,000.00 | |
| Sector | Health Technology | Employees | 76 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MLYS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.576 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.546 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
MLYS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,034,881.579 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MLYS Liquidity
| Current Ratio | 43.763 |
| Quick Ratio | 43.763 |
| Cash Ratio | 43.448 |
MLYS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -35.646 |
| Return on Equity | -36.912 |
| Return on Total Capital | -23.914 |
| Return on Invested Capital | -36.912 |
MLYS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Mineralys Therapeutics Inc - MLYS
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| - | - | 43.00K | 59.00K | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | 43.00K | 59.00K | - |
Depreciation
| - | - | 43.00K | 59.00K | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | +37.21% | - |
Gross Income
| - | - | (43.00K) | (59.00K) | - |
Gross Income Growth
| - | - | - | -37.21% | - |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 31.48M | 84.66M | 192.36M | 170.54M | |
Research & Development
| 26.25M | 70.36M | 168.58M | 132.01M | |
Other SG&A
| 5.23M | 14.30M | 23.78M | 38.54M | |
SGA Growth
| +68.11% | +168.93% | +127.22% | -11.34% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (31.48M) | (84.66M) | (192.40M) | (170.60M) | |
Non Operating Income/Expense
| 1.68M | 12.76M | 14.59M | 15.95M | |
Non-Operating Interest Income
| 1.68M | 12.76M | 14.59M | 15.95M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | -100.00% | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (29.80M) | (71.90M) | (177.81M) | (154.65M) | |
Pretax Income Growth
| -53.54% | -141.28% | -147.31% | +13.02% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (29.80M) | (71.90M) | (177.81M) | (154.65M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (29.80M) | (71.90M) | (177.81M) | (154.65M) | |
Net Income Growth
| -53.54% | -141.28% | -147.31% | +13.02% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (29.80M) | (71.90M) | (177.81M) | (154.65M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (29.80M) | (71.90M) | (177.81M) | (154.65M) | |
EPS (Basic)
| -0.7294 | -1.9868 | -3.6632 | -2.2858 | |
EPS (Basic) Growth
| -102.27% | -172.39% | -84.38% | +37.60% | |
Basic Shares Outstanding
| 40.86M | 36.19M | 48.54M | 67.66M | |
EPS (Diluted)
| -0.7294 | -1.9868 | -3.6632 | -2.2858 | |
EPS (Diluted) Growth
| -102.27% | -172.39% | -84.38% | +37.60% | |
Diluted Shares Outstanding
| 40.86M | 36.19M | 48.54M | 67.66M | |
EBITDA
| (31.48M) | (84.66M) | (192.36M) | (170.54M) | |
EBITDA Growth
| -68.11% | -168.93% | -127.22% | +11.34% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 50.875 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.515 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -2.192 | |
| Last Quarter’s Earnings | -0.463 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.29 | Next Fiscal Year Estimate | -1.863 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 6 | 7 |
| Mean Estimate | -0.52 | -0.55 | -2.19 | -1.86 |
| High Estimates | -0.43 | -0.45 | -1.76 | 1.01 |
| Low Estimate | -0.61 | -0.60 | -2.53 | -2.74 |
| Coefficient of Variance | -11.43 | -9.33 | -12.16 | -71.71 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Mineralys Therapeutics Inc - MLYS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Mineralys Therapeutics Inc - MLYS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 254,519 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.25 per share | 3,626,895.75 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 108,334 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 6,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 44,440 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 175,807 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 84,018 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 160,653 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 16,371 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 72,478 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 61,804 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $35.53 per share | 2,195,896.12 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 115,274 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.83 per share | 4,014,993.42 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 81,888 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.08 per share | 88,439.04 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 187,046 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16 per share | 2,992,736.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 133,416 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $10.2 per share | 1,360,843.20 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 107,347 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $15.44 per share | 1,657,437.68 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 97,226 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.08 per share | 105,004.08 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 69,188 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $35.87 per share | 2,481,773.56 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 139,225 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.25 per share | 1,983,956.25 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 115,032 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16 per share | 1,840,512.00 |
| Jan 8, 2026 | David M. Rodman Chief Medical Officer | 94,864 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $10.2 per share | 967,612.80 |